A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area
Jemal Hussein, Martha Zewdie, Lawrence Yamuah, Ahmed Bedru, Markos Abebe, Alemnew F Dagnew, Menberework Chanyalew, Asfawesen G Yohannes, Jemal Ahmed, Howard Engers, T Mark Doherty, Peter Bang, Ingrid Kromann, Søren T Hoff, Abraham Aseffa, Jemal Hussein, Martha Zewdie, Lawrence Yamuah, Ahmed Bedru, Markos Abebe, Alemnew F Dagnew, Menberework Chanyalew, Asfawesen G Yohannes, Jemal Ahmed, Howard Engers, T Mark Doherty, Peter Bang, Ingrid Kromann, Søren T Hoff, Abraham Aseffa
Abstract
Background: H1/IC31® is a tuberculosis (TB) subunit vaccine candidate consisting of the fusion protein of Ag85B and ESAT-6 (H1) formulated with the IC31® adjuvant. Previous trials have reported on the H1/IC31® vaccine in M. tuberculosis (Mtb)-naïve, BCG-vaccinated and previously Mtb-infected individuals. In this trial, conducted between December 2008 and April 2010, the safety and immunogenicity of H1/IC31® was assessed in participants living in Ethiopia - a highly TB-endemic area.
Methods: Healthy male participants aged 18-25 years were recruited into four groups. Participants in group 1 (N = 12) and group 2 (N = 12) were Tuberculin Skin Test (TST) negative and QuantiFERON-TB Gold in-tube test (QFT) negative (Mtb-naïve groups), participants in group 3 (N = 3) were TST positive and QFT negative (BCG group), and participants in group 4 (N = 12) were both TST and QFT positive (Mtb-infected group). H1 vaccine alone (group 1) or H1 formulated with the adjuvant IC31® (groups 2, 3 and 4) was administered intramuscularly on day 0 and day 56. Safety and immunogenicity parameters were evaluated for up to 32 weeks after day 0.
Results: The H1/IC31®vaccine was safe and generally well tolerated. There was little difference among the four groups, with a tendency towards a higher incidence of adverse events in Mtb-infected compared to Mtb-naïve participants. Two serious adverse events were reported in the Mtb-infected group where a relationship to the vaccine could not be excluded. In both cases the participants recovered without sequelae within 72 h. Immunogenicity assays, evaluated in the 29 participants who received both vaccinations, showed a stronger response to TB antigens in the Mtb-naïve group vaccinated with the adjuvant.
Conclusion: The trial confirmed the need for an adjuvant for the vaccine to be immunogenic and highlighted the importance of early phase testing of a novel TB vaccine candidate in TB-endemic areas.
Trial registration: ClinicalTrials.gov, ID: NCT01049282. Retrospectively registered on 14 January 2010.
Keywords: Immunogenicity; Tuberculosis; Vaccines.
Conflict of interest statement
Ethics approval and consent to participateThe trial application was reviewed and approved by the Danish National Committee on Biomedical Research Ethics; the Institutional Review Board at the investigation site, Armauer Hansen Research Institute (AHRI), All Africa Leprosy Rehabilitation and Training Centre (ALERT) Ethical Review Committee; and the National Research Ethics Review Committee of Ethiopia. Written informed consent was obtained from all participants.
Consent for publicationNot applicable
Competing interestsPB and IK are employed at Staten Serum Institut which owns the H1/IC31® vaccine rights. MD and AFD are currently employed at Glaxo-Smith Kline (GSK); SH is employed at Novo Nordisk, but none of the described work is funded by GSK or Novo Nordisk and the views described here are solely those of the authors. No other conflicts of interest were identified.
Publisher’s NoteSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures
References
- WHO. Global Tuberculosis Report 2013 [Internet]. Cited 2014 Jul 29. Available from [].
- Roy A, Eisenhut M, Harris RJ, Rodrigues LC, Sridhar S, Habermann S, Snell L, Mangtani P, Adetifa I, Lalvani A, et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ. 2014;349:g4643. doi: 10.1136/bmj.g4643.
- Abubakar I, Pimpin L, Ariti C, Beynon R, Mangtani P, Sterne JA, Fine PE, Smith PG, Lipman M, Elliman D, et al. Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guerin vaccination against tuberculosis. Health Technol Assess. 2013;17(37):1–372. doi: 10.3310/hta17370.
- Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, Fineberg HV. The efficacy of bacillus Calmette-Guerin vaccination of newborn and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics. 1995;96(1):29–35.
- Andersen P, Woodworth JS. Tuberculosis vaccines—rethinking the current paradigm. Trends Immunol. 2014;35(8):387–395. doi: 10.1016/j.it.2014.04.006.
- Hawn TR, Day TA, Scriba TJ, Hatherill M, Hanekom WA, Evans TG, Churchyard GJ, Kublin JG, Bekker LG, Self SG. Tuberculosis vaccines and prevention of infection. Microbiol Mol Biol Rev. 2014;78(4):650–671. doi: 10.1128/MMBR.00021-14.
- Andersen P, Kaufmann SHE. Novel vaccination strategies against tuberculosis. Cold Spring Harb Perspect Med. 2014;4(6):a018523. doi: 10.1101/cshperspect.a018523.
- Brodin P, Majlessi L, Marsollier L, de Jonge MI, Bottai D, Demangel C, Hinds J, Neyrolles O, Butcher PD, Leclerc C, et al. Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence. Infect Immun. 2006;74(1):88–98. doi: 10.1128/IAI.74.1.88-98.2006.
- Harboe M, Oettinger T, Wiker HG, Rosenkrands I, Andersen P. Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect Immun. 1996;64(1):16–22.
- Mustafa AS, Shaban FA, Abal AT, Al-Attiyah R, Wiker HG, Lundin KEA, Oftung F, Huygen K. Identification and HLA restriction of naturally derived Th1-Cell epitopes from the secreted Mycobacterium tuberculosis antigen 85B recognized by antigen-specific human CD4+ T-Cell lines. Infect Immun. 2000;68(7):3933–3940. doi: 10.1128/IAI.68.7.3933-3940.2000.
- Copin R, Coscolla M, Efstathiadis E, Gagneux S, Ernst JD. Impact of in vitro evolution on antigenic diversity of Mycobacterium bovis bacillus Calmette-Guerin (BCG) Vaccine. 2014;32(45):5998–6004. doi: 10.1016/j.vaccine.2014.07.113.
- Hoang T, Aagaard C, Dietrich J, Cassidy JP, Dolganov G, Schoolnik GK, Lundberg CV, Agger EM, Andersen P. ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre- and post-exposure tuberculosis vaccination. PLoS One. 2013;8(12):e80579. doi: 10.1371/journal.pone.0080579.
- Schellack C, Prinz K, Egyed A, Fritz JH, Wittmann B, Ginzler M, Swatosch G, Zauner W, Kast C, Akira S, et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine. 2006;24(26):5461–5472. doi: 10.1016/j.vaccine.2006.03.071.
- van Dissel JT, Arend SM, Prins C, Bang P, Tingskov PN, Lingnau K, Nouta J, Klein MR, Rosenkrands I, Ottenhoff TH, et al. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. Vaccine. 2010;28(20):3571–3581. doi: 10.1016/j.vaccine.2010.02.094.
- van Dissel JT, Soonawala D, Joosten SA, Prins C, Arend SM, Bang P, Tingskov PN, Lingnau K, Nouta J, Hoff ST, et al. Ag85B-ESAT-6 adjuvanted with IC31(R) promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection. Vaccine. 2011;29(11):2100–2109. doi: 10.1016/j.vaccine.2010.12.135.
- Reither K, Katsoulis L, Beattie T, Gardiner N, Lenz N, Said K, Mfinanga E, Pohl C, Fielding KL, Jeffery H, et al. Safety and immunogenicity of H1/IC31(R), an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial. PLoS One. 2014;9(12):e114602. doi: 10.1371/journal.pone.0114602.
- Mearns H, Geldenhuys HD, Kagina BM, Musvosvi M, Little F, Ratangee F, Mahomed H, Hanekom WA, Hoff ST, Ruhwald M, et al. H1:IC31 vaccination is safe and induces long-lived TNF-alpha + IL-2 + CD4 T cell responses in M. tuberculosis infected and uninfected adolescents: a randomized trial. Vaccine. 2017;35(1):132–141. doi: 10.1016/j.vaccine.2016.11.023.
- Wassie L, Aseffa A, Abebe M, Gebeyehu MZ, Zewdie M, Mihret A, Erenso G, Chanyalew M, Tilahun H, Yamuah LK, et al. Parasitic infection may be associated with discordant responses to QuantiFERON and tuberculin skin test in apparently healthy children and adolescents in a tuberculosis endemic setting, Ethiopia. BMC Infect Dis. 2013;13:265. doi: 10.1186/1471-2334-13-265.
- du Plessis N, Walzl G. Helminth-M. tb co-infection. Adv Exp Med Biol. 2014;828:49–74. doi: 10.1007/978-1-4939-1489-0_3.
- Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis. 2006;10(11):1192–1204.
- Weir RE, Gorak-Stolinska P, Floyd S, Lalor MK, Stenson S, Branson K, Blitz R, Ben-Smith A, Fine PE, Dockrell HM. Persistence of the immune response induced by BCG vaccination. BMC Infect Dis. 2008;8:9. doi: 10.1186/1471-2334-8-9.
- van Dissel JT, Joosten SA, Hoff ST, Soonawala D, Prins C, Hokey DA, O’Dee DM, Graves A, Thierry-Carstensen B, Andreasen LV, et al. A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human. Vaccine. 2014;32(52):7098–7107. doi: 10.1016/j.vaccine.2014.10.036.
- Luabeya AK, Kagina BM, Tameris MD, Geldenhuys H, Hoff ST, Shi Z, Kromann I, Hatherill M, Mahomed H, Hanekom WA, et al. First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults. Vaccine. 2015;33(33):4130–4140. doi: 10.1016/j.vaccine.2015.06.051.
Source: PubMed